BR0113312A - Tetrazol, composição farmacêutica que compreende o mesmo, processo para a preparação dessa composição, utilização dos compostos, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii, processo para a preparação de um tetrazol e compostos resultantes - Google Patents

Tetrazol, composição farmacêutica que compreende o mesmo, processo para a preparação dessa composição, utilização dos compostos, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii, processo para a preparação de um tetrazol e compostos resultantes

Info

Publication number
BR0113312A
BR0113312A BR0113312-8A BR0113312A BR0113312A BR 0113312 A BR0113312 A BR 0113312A BR 0113312 A BR0113312 A BR 0113312A BR 0113312 A BR0113312 A BR 0113312A
Authority
BR
Brazil
Prior art keywords
compounds
type
composition
tetrazole
diabetes
Prior art date
Application number
BR0113312-8A
Other languages
English (en)
Portuguese (pt)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0113312A publication Critical patent/BR0113312A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0113312-8A 2000-08-15 2001-08-09 Tetrazol, composição farmacêutica que compreende o mesmo, processo para a preparação dessa composição, utilização dos compostos, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii, processo para a preparação de um tetrazol e compostos resultantes BR0113312A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22549400P 2000-08-15 2000-08-15
PCT/EP2001/009207 WO2002014312A1 (en) 2000-08-15 2001-08-09 Tetrazolyl-phenyl acetamide glucokinase activators

Publications (1)

Publication Number Publication Date
BR0113312A true BR0113312A (pt) 2003-07-01

Family

ID=22845106

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0113312-8A BR0113312A (pt) 2000-08-15 2001-08-09 Tetrazol, composição farmacêutica que compreende o mesmo, processo para a preparação dessa composição, utilização dos compostos, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii, processo para a preparação de um tetrazol e compostos resultantes

Country Status (20)

Country Link
US (3) US6369232B1 (cg-RX-API-DMAC7.html)
EP (1) EP1311504B1 (cg-RX-API-DMAC7.html)
JP (1) JP3961948B2 (cg-RX-API-DMAC7.html)
KR (1) KR100518061B1 (cg-RX-API-DMAC7.html)
CN (1) CN1209362C (cg-RX-API-DMAC7.html)
AR (1) AR031718A1 (cg-RX-API-DMAC7.html)
AT (1) ATE297921T1 (cg-RX-API-DMAC7.html)
AU (2) AU2001283998B2 (cg-RX-API-DMAC7.html)
BR (1) BR0113312A (cg-RX-API-DMAC7.html)
CA (1) CA2419416C (cg-RX-API-DMAC7.html)
DE (1) DE60111540T2 (cg-RX-API-DMAC7.html)
DK (1) DK1311504T3 (cg-RX-API-DMAC7.html)
ES (1) ES2243541T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA03001275A (cg-RX-API-DMAC7.html)
PA (1) PA8525201A1 (cg-RX-API-DMAC7.html)
PE (1) PE20020386A1 (cg-RX-API-DMAC7.html)
PT (1) PT1311504E (cg-RX-API-DMAC7.html)
UY (1) UY26885A1 (cg-RX-API-DMAC7.html)
WO (1) WO2002014312A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200300904B (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
US7078423B2 (en) * 2002-07-18 2006-07-18 Inotek Pharmaceuticals Corporation 5-Aryltetrazole compounds, compositions thereof, and uses therefor
US7087631B2 (en) * 2002-07-18 2006-08-08 Inotek Pharmaceuticals Corporation Aryltetrazole compounds, and compositions thereof
WO2004050645A1 (en) * 2002-10-03 2004-06-17 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
MY141521A (en) 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
WO2004063194A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company Heteroaryl compounds
US7262196B2 (en) * 2003-02-11 2007-08-28 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
BRPI0509543A (pt) * 2004-04-02 2007-09-18 Novartis Ag derivados de tiazolopiridina, condições farmacêuticas que contêm os mesmos e métodos para tratar condições mediadas por glucocinase
EP1735322B1 (en) * 2004-04-02 2011-09-14 Novartis AG Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful for the treatment of type 2 diabetes
EP2301935A1 (en) 2005-07-09 2011-03-30 AstraZeneca AB (Publ) Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
KR100965040B1 (ko) * 2005-07-11 2010-06-21 미쓰비시 타나베 파마 코퍼레이션 옥심 유도체 및 그의 제조 방법
CA2621227A1 (en) 2005-08-31 2007-03-08 Astellas Pharma Inc. Thiazole derivative
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
CN101272784A (zh) 2005-09-29 2008-09-24 塞诺菲-安万特股份有限公司 苯基-和吡啶基-1,2,4-噁二唑酮衍生物、它们的制备方法和它们作为药物的用途
GT200600428A (es) * 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) * 2005-09-30 2007-04-30 Compuestos organicos
BRPI0618062A2 (pt) * 2005-11-03 2011-08-16 Prosidion Ltd composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para a preparação de um composto
US20070197532A1 (en) * 2005-11-18 2007-08-23 Cao Sheldon X Glucokinase activators
ES2381864T3 (es) * 2005-12-15 2012-06-01 Nihon Nohyaku Co., Ltd. Derivado de ftalamida, pesticida agrícola u hortícola y utilización del pesticida
WO2007104034A2 (en) 2006-03-08 2007-09-13 Takeda San Diego, Inc. Glucokinase activators
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2049518B1 (en) * 2006-05-31 2011-08-31 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents.
US7910747B2 (en) * 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
US7902248B2 (en) 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
WO2008079787A2 (en) 2006-12-20 2008-07-03 Takeda San Diego, Inc. Glucokinase activators
TW200831081A (en) * 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
EP2105435A4 (en) * 2007-01-10 2011-06-15 Mitsubishi Tanabe Pharma Corp Hydrazone derivative
WO2008111473A1 (ja) * 2007-03-07 2008-09-18 Kyorin Pharmaceutical Co., Ltd. グルコキナーゼ活性化物質
WO2008116107A2 (en) * 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
AU2008310519B2 (en) * 2007-10-08 2013-05-02 Advinus Therapeutics Private Limited Acetamide derivatives as glucokinase activators, their process and medicinal applications
AR070107A1 (es) * 2008-01-15 2010-03-17 Lilly Co Eli R-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida en forma cristalina, composicion farmaceutica que la comprende y su uso para la manufactura de un medicamento util para la prevencion o tratamiento de hiperglicemia
KR20100113518A (ko) * 2008-01-18 2010-10-21 아스텔라스세이야쿠 가부시키가이샤 페닐아세트아미드 유도체
JP5449144B2 (ja) * 2008-04-28 2014-03-19 杏林製薬株式会社 シクロペンチルアクリル酸アミド誘導体
ES2893699T3 (es) 2010-03-31 2022-02-09 Scripps Research Inst Reprogramación de células

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3776917A (en) * 1972-06-05 1973-12-04 Schering Corp 2-amino-6-phenalkyl-aminopyridines and derivatives thereof
GB8909574D0 (en) 1989-04-26 1989-06-14 Ici Plc Chemical process
US5859052A (en) * 1993-01-14 1999-01-12 G. D. Searle & Co. Fatty acid analogs and prodrugs
US5461049A (en) * 1994-05-27 1995-10-24 Warner-Lambert Company Amide tetrazole ACAT inhibitors
US5468867A (en) * 1994-05-27 1995-11-21 Syntex (U.S.A.) Inc. Process for preparing1-butyl-2-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl1-1H-indole-3-carboxylic acid
JP2001509166A (ja) * 1997-01-28 2001-07-10 メルク エンド カンパニー インコーポレーテッド 糖尿病および肥満の治療のためのβ▲下３▼作動薬としてのチアゾールベンゼンスルホンアミド
PT1169312E (pt) * 1999-03-29 2005-01-31 Hoffmann La Roche Activadores de glicocinase

Also Published As

Publication number Publication date
AU8399801A (en) 2002-02-25
JP3961948B2 (ja) 2007-08-22
PT1311504E (pt) 2005-10-31
ATE297921T1 (de) 2005-07-15
MXPA03001275A (es) 2003-06-30
EP1311504B1 (en) 2005-06-15
UY26885A1 (es) 2002-02-28
ZA200300904B (en) 2004-04-30
DE60111540T2 (de) 2006-03-16
CN1466584A (zh) 2004-01-07
PE20020386A1 (es) 2002-05-13
ES2243541T3 (es) 2005-12-01
CN1209362C (zh) 2005-07-06
EP1311504A1 (en) 2003-05-21
US20020035266A1 (en) 2002-03-21
US20020065275A1 (en) 2002-05-30
US6441180B1 (en) 2002-08-27
KR20030022408A (ko) 2003-03-15
PA8525201A1 (es) 2002-07-30
CA2419416A1 (en) 2002-02-21
JP2004506632A (ja) 2004-03-04
WO2002014312A1 (en) 2002-02-21
DK1311504T3 (da) 2005-10-17
DE60111540D1 (de) 2005-07-21
AU2001283998B2 (en) 2005-10-20
KR100518061B1 (ko) 2005-09-28
US6369232B1 (en) 2002-04-09
US6388088B1 (en) 2002-05-14
CA2419416C (en) 2009-10-13
US20020035267A1 (en) 2002-03-21
AR031718A1 (es) 2003-10-01

Similar Documents

Publication Publication Date Title
BR0113312A (pt) Tetrazol, composição farmacêutica que compreende o mesmo, processo para a preparação dessa composição, utilização dos compostos, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii, processo para a preparação de um tetrazol e compostos resultantes
BR0110492A (pt) Composto, composição farmacêutica que compreende esse composto, processo para a preparação de composição farmacêutica, utilização do composto e processo para a preparação do composto
BR0317268A (pt) Compostos ativadores da pirazina e da piridina glucoquinase 5-substituìda, composição farmacêutica, uso e processo de preparação dos mesmos
BRPI0212775B8 (pt) composto de 1,2,4-triazol e medicamento
BR0114708A (pt) Compostos, composições farmacêuticas que compreendem os mesmos, utilização dos compostos, processo de tratamento de distúrbios e de obesidade, e processos para a preparação dos compostos e de uma composição
NO20033385D0 (no) Fuserte heterocykliske forbindelser
ATE381542T1 (de) Nr1h4-kern-rezeptor-bindende verbindungen
PE20061357A1 (es) COMPUESTOS DERIVADOS DE AMINOSULFONILO COMO INHIBIDORES DE LA 11-ß-HSD-1
DK1716152T3 (da) Kondenserade heterocykliske forbindelser og deres anvendelse som metabotrope receptorantagonister til behandling af gastrointentinde lidelser
WO2000063208B1 (en) Substituted imidazoles, their preparation and use
BR0110704A (pt) Fenil - acetamidas substituìdas e seu uso como ativadores de glicocinase
BR0110573A (pt) Composto, composição farmacêutica que compreende esse composto, processo para a preparação de uma composição farmacêutica, utilização do composto e processo para o tratamento profilático ou terapêutico e para a preparação do composto
BRPI0416004A (pt) composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método para o tratamento de doenças mediadas por glk, uso de um composto ou um sal, solvato ou pró-droga do mesmo, métodos para o tratamento combinado de obesidade e diabetes e para o tratamento de obesidade, e, processo para a preparação de um composto ou um sal, pró-droga ou solvato do mesmo
BR0009320A (pt) Dibenzopiranos como antagonistas do receptor glicocorticóide para o tratamento da diabete
BR0213660A (pt) Composto, composição farmacêutica e método para tratar pacientes
CO5690638A2 (es) Nuevos compuestos triciclicos utiles para el tratamiento de desordenes inflamatorios y alergicos; proceso para su preparacion y composiciones farmaceuticas que los contienen
WO2008079683A3 (en) N- (5, 6, 7, 8-tetrahydronaphthalen-1-yl) urea derivatives and related compounds as trpv1 vanilloid receptor antagonists for the treatment of pain
ATE556067T1 (de) Modulatoren des vanilloid rezeptors
UY28528A1 (es) Nuevos compuestos
ATE457971T1 (de) Derivate von 4-hydroxybutansäure und deren höheren homologen als liganden von g- hydroxybutyrat- (gbh-)rezeptoren, pharmazeutische zusammensetzungen, die diese enthalten, und pharmazeutische anwendungen
MY139454A (en) 4-(aminomethyl)-piperidine benzamides as 5ht4-antagonists
BR0313377A (pt) Bifenilcarnboxamidas substituìdas por n-aril piperidina como inibidores de secreção de apolipoproteìna b
BRPI0407968A (pt) derivados de oxamida úteis como inibidores de raf-quinase
MX2007008308A (es) Derivados de n-(heteroaril)-1h-indol-2-carboxamidas y su utilizacion como ligandos del receptor vaniloide trpv1-.
AR037521A1 (es) Derivados de piperazina que tienen actividad antagonista del sst1, un proceso para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de la depresion, ansiedad y padecimientos bipolares y una combinacion

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2125 DE 27/09/2011.